Literature DB >> 11358966

The role of zinc binding in the biological activity of botulinum toxin.

L L Simpson1, A B Maksymowych, S Hao.   

Abstract

Botulinum toxin is a zinc-dependent endoprotease that acts on vulnerable cells to cleave polypeptides that are essential for exocytosis. To exert this poisoning effect, the toxin must proceed through a complex sequence of events that involves binding, productive internalization, and intracellular expression of catalytic activity. Results presented in this study show that soluble chelators rapidly strip Zn(2+) from its binding site in botulinum toxin, and this stripping of cation results in the loss of catalytic activity in cell-free or broken cell preparations. Stripped toxin is still active against intact neuromuscular junctions, presumably because internalized toxin binds cytosolic Zn(2+). In contrast to soluble chelators, immobilized chelators have no effect on bound Zn(2+), nor do they alter toxin activity. The latter finding is because of the fact that the spontaneous loss of Zn(2+) from its coordination site in botulinum toxin is relatively slow. When exogenous Zn(2+) is added to toxin that has been stripped by soluble chelators, the molecule rebinds cation and regains catalytic and neuromuscular blocking activity. Exogenous Zn(2+) can restore toxin activity either when the toxin is free in solution on the cell exterior or when it has been internalized and is in the cytosol. The fact that stripped toxin can reach the cytosol means that the loss of bound Zn(2+) does not produce conformational changes that block internalization. Similarly, the fact that stripped toxin in the cytosol can be reactivated by ambient Zn(2+) or exogenous Zn(2+) means that productive internalization does not produce conformational changes that block rebinding of cation.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11358966     DOI: 10.1074/jbc.M102172200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  8 in total

1.  The role of exoproteases in governing intraneuronal metabolism of botulinum toxin.

Authors:  Lance L Simpson; Andrew B Maksymowych; Hirokazu Kouguchi; Garrett Dubois; Roop S Bora; Suresh Joshi
Journal:  Protein J       Date:  2005-04       Impact factor: 2.371

2.  Comparison of extracellular and intracellular potency of botulinum neurotoxins.

Authors:  Fang Cai; Carrie B Adrion; James E Keller
Journal:  Infect Immun       Date:  2006-10       Impact factor: 3.441

3.  Trivalent vaccine against botulinum toxin serotypes A, B, and E that can be administered by the mucosal route.

Authors:  Easwaran Ravichandran; Fetweh H Al-Saleem; Denise M Ancharski; Mohammad D Elias; Ajay K Singh; Mohammad Shamim; Yujing Gong; Lance L Simpson
Journal:  Infect Immun       Date:  2007-03-19       Impact factor: 3.441

4.  Localization of the sites and characterization of the mechanisms by which anti-light chain antibodies neutralize the actions of the botulinum holotoxin.

Authors:  Tsuyoshi Takahashi; Suresh G Joshi; Fetweh Al-Saleem; Denise Ancharski; Ajay Singh; Zidoon Nasser; Lance L Simpson
Journal:  Vaccine       Date:  2009-02-24       Impact factor: 3.641

Review 5.  Drug Insight: biological effects of botulinum toxin A in the lower urinary tract.

Authors:  Michael B Chancellor; Clare J Fowler; Apostolos Apostolidis; William C de Groat; Christopher P Smith; George T Somogyi; K Roger Aoki
Journal:  Nat Clin Pract Urol       Date:  2008-05-06

Review 6.  Botulinum Toxin Injection for Treatment of Chronic Anal Fissure: Is There Any Dose-Dependent Efficiency? A Meta-Analysis.

Authors:  Adam Bobkiewicz; Wojciech Francuzik; Lukasz Krokowicz; Adam Studniarek; Witold Ledwosiński; Jacek Paszkowski; Michal Drews; Tomasz Banasiewicz
Journal:  World J Surg       Date:  2016-12       Impact factor: 3.352

7.  Botulinum toxin for the treatment of myofascial pain syndromes involving the neck and back: a review from a clinical perspective.

Authors:  José M Climent; Ta-Shen Kuan; Pedro Fenollosa; Francisco Martin-Del-Rosario
Journal:  Evid Based Complement Alternat Med       Date:  2013-02-19       Impact factor: 2.629

8.  Attomolar detection of botulinum toxin type A in complex biological matrices.

Authors:  Karine Bagramyan; Jason R Barash; Stephen S Arnon; Markus Kalkum
Journal:  PLoS One       Date:  2008-04-30       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.